CMR Surgical
Cambridge-based maker of the Versius modular surgical robot, founded in 2014. It announced a strategic alliance with Stryker in October 2026 that includes about 400 million dollars of preferred equity.
Industry: Surgical robotics | Location: Cambridge, United Kingdom | Founded: 2014 | Total Funding: USD 1.2B
About CMR Surgical
CMR Surgical Ltd is a private limited company registered in England with headquarters in Cambridge. It makes Versius, a modular robotic system for soft tissue minimal access surgery. In March 2026 the company said more than 45,000 patients had been treated with Versius and that hospitals in over 30 countries had adopted it. A 2024 company release said it had been used in the Middle East, among other regions.
CMR says five founders started the company in 2014 but does not name them on its about page. Co-founders Luke Hares and Mark Slack, formerly chief innovation officer and chief medical officer, moved to advisory roles in an announcement dated 29 September 2026. Massimiliano Colella has been chief executive since January 2025, after serving as interim chief executive from October 2024; he joined in 2023 as chief commercial officer. Daniel Moore became non-executive chairman in July 2024.
Versius received a CE mark in 2019. In October 2024 the US Food and Drug Administration authorized it through the De Novo process, and in December 2025 the agency cleared Versius Plus for cholecystectomy in adults aged 22 and older.
Global Venturing reported a 46 million dollar Series A in 2017, a 100 million dollar Series B in 2018 and a 240 million dollar Series C in September 2019. A 600 million dollar Series D in June 2021 was co-led by SoftBank Vision Fund 2 and Ally Bridge Group, at a valuation of about 3 billion dollars according to the Financial Times, cited by Unquote. On 4 April 2025 CMR announced more than 200 million dollars in equity and debt, including a debt investment from Trinity Capital.
On 12 October 2026 CMR and Stryker announced a strategic alliance. Stryker will invest about 400 million dollars in preferred equity, receive an exclusive option to buy the rest of CMR's equity and become the exclusive US sales agent for Versius. The investment remains subject to customary closing conditions.
CMR's management team includes Basel Abou Jalala as commercial senior vice president and general manager for the Middle East and Africa, Asia-Pacific and Latin America,.
Leadership
- Luke Hares, Co-founder and Chief Innovation Officer (moving to advisory role)
- Mark Slack, Co-founder and Chief Medical Officer (moving to advisory role)
- Massimiliano Colella, Chief Executive Officer
- Daniel Moore, Non-Executive Chairman
- Andre Nel, Chief Financial Officer
- Chris Fryer, Chief Technology Officer
- Basel Abou Jalala, Commercial Senior Vice President, General Manager MEA, APAC and LatAm
- Chris O'Hara, Commercial President and General Manager, US